Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 6, 2010, Pages 835-843

  Derosa, Giuseppe ^a   Maffioli, Pamela ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Amlodipine; Atorvastatin; Combination; Hypercholesterolemia; Hypertension

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS ATORVASTATIN; ATORVASTATIN; PLACEBO; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; DRUG COMBINATION; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ANKLE EDEMA; ARTERY COMPLIANCE; ARTHRALGIA; ASTHENIA; BLOOD PRESSURE REGULATION; BODY RASH; CLINICAL TRIAL; CONSTIPATION; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; HEART LEFT VENTRICLE MASS; HEART PALPITATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; MONOTHERAPY; MYALGIA; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; SOMNOLENCE; STOMACH DISCOMFORT; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; PYRROLES; HYPOLIPIDEMIC AGENTS;

EID: 77953500562     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.51     Document Type: Review

References (38)

1. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363, 2022-2031 (2004).
2. Nissen SE. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Am. J. Cardiol. 96, 61-68 (2005).
3. LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352, 1425-1435 (2005).
4. Dahlöf B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trail-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366, 895-906 (2005).
5. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292, 2217-2225 (2004).
6. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350, 1495-1504 (2004).
7. Sever PS, Dahlöf B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trail-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361, 1149-1158 (2003).
8. Sever P, Dahlöf B, Poulter N et al. Potential synergy between lipid-lowering and blood-pressure lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur. Heart J. 27, 2982-2988 (2006). Caduet® . Package insert. Pfizer Inc., NY, USA.
9. Chung M, Calcagni A, Glue P, Bramson C. Bioavailability of amlodipine besylate/ atorvastatin calcium combination tablet. J. Clin. Pharmacol. 46, 1030-1037 (2006).
10. Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291, 1071-1080 (2004). Norvasc® . Package insert. Pfizer Inc., NY, USA. (Pubitemid 38541684)
11. Lipitor® . Package insert. Pfizer Inc., NY, USA.
12. Bellosta S, Ferri N, Arnaboldi L, Bernini F, Paoletti R, Corsini A. Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care 23, 72-78 (2000).
13. Nicholls SJ, Tuzcu EM, Sipahi I et al. Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study). Am. J. Cardiol. 97, 1553-1557 (2006).
14. Schoenhagen P, Tuzcu EM, Apperson-Hansen C et al. Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial. Circulation 113, 2826-2834 (2006). (Pubitemid 44305295)
15. Ridker PM, Rifai N, Pfeffer MA et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 98, 839-844 (1998).
16. Cohn JN, Wilson DJ, Neutel J et al. Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. Am. J. Hypertens. 22, 137-144 (2009).
17. Cohn JN. Pathophysiologic and prognostic implications of measuring arterial compliance in hypertensive disease. Prog. Cardiovasc. Dis. 41, 441-450 (1999).
18. Fogari R, Derosa G, Lazzari P et al. Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. Am. J. Hypertens. 17(9), 823-827 (2004).
19. Fogari R, Preti P, Zoppi A et al. Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. Eur. J. Clin. Pharmacol. 62(10), 817-822 (2006).
20. Erdine S, Ro YM, Tse HF et al. Single-pill amlodipine-atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). J. Hum. Hypertens. 23(3), 196-210 (2009).
21. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 289, 2560-2572 (2003).
22. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285, 2486-2497 (2001).
23. Flack JM, Victor R, Watson K et al. Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. Mayo Clin. Proc. 83(1), 35-45 (2008).
24. Neutel JM, Bestermann MH, Dyess EM et al. The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study. J. Clin. Hypertens. 11(1), 22-30 (2009).
25. Preston RA, Harvey P, Herfert O et al. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. J. Clin. Pharmacol. 47(12), 1555-1569 (2007).
26. Ge CJ, Lu SZ, Chen YD, Wu XF, Hu SJ, Ji Y. Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. Heart. Vessels 23(2), 91-95 (2008).
27. Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y. Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. Hypertension 47, 195-202 (2006).
28. Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J. Biol. Chem. 266, 8604-8608 (1991).
29. Khosla UM, Zharikov S, Finch JL et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 67, 1739-1742 (2005).
30. Martín-Ventura JL, Muñoz-Garcia B, Blanco-Colio LM et al. Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis. Kidney Int. Suppl. 111, S71-S74 (2008).
31. Gilani M, Kaiser DR, Bratteli CW et al. Role of nitric oxide deficiency and its detection as a risk factor in pre-hypertension. J. Am. Soc. Hypertens. 1, 45-55 (2007).
32. Grey E, Bratteli C, Glasser SP et al. Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular events. Am. J. Hypertens. 16, 265-269 (2003).
33. McVeigh GE, Bratteli CW, Morgan DJ et al. Age-related abnormalities in arterial compliance identified by pressure pulse contour analysis: aging and arterial compliance. Hypertension 33, 1392-1398 (1999).
34. Sugiyama M, Ohashi M, Takase H, Sato K, Ueda R, Dohi Y. Effects of atorvastatin on inflammation and oxidative stress. Heart Vessels 20, 133-136 (2005).
35. Lijnen HR, Collen D. Endothelium in hemostasis and thrombosis. Prog. Cardiovasc. Dis. 22(Suppl. 4), S1-S14 (1993).
36. Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases. J. Cardiovasc. Pharmacol. 22(Suppl. 4), S1-S14 (1993).
37. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann. Intern. Med. 114, 345-352 (1991).
38. Bangalore S, Kamalakkannan G, Parker S et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am. J. Med. 120, 713-719 (2007).